Phase 3 ECHO: Safety Data Review

Two hematologic oncologists defined rare lymphomas and highlighted challenges and recent developments associated with these disease types.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

A phase 1 trial is evaluating UB-VV111 with and without rapamycin as treatment for patients with CLL and LBCL who received at least 2 prior therapies.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Two teams of lymphoma experts engage in a face-off competition, showcasing real-world updates, patient cases, and use of ASCT or CAR T-cell therapy.

Results from the phase 2 MorningSun trial demonstrated that outpatient, subcutaneous single-agent mosunetuzumab was efficacious in patients with marginal zone lymphoma.